Cisplatin versus carboplatin: Comparative review of therapeutic management in solid malignancies

Critical Reviews in Oncology/Hematology

Volumn 102, Issue , 2016, Pages 37-46

  Ho, Gwo Yaw ^a,b,d   Woodward, Natasha ^b   Coward, Jermaine I G ^a,b,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b MATER HOSPITAL   (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

^d WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Carboplatin; Cisplatin; Platinum resistance; Platinum sensitivity; Platinum based chemotherapy; Radio sensitisation

Indexed keywords

BIOLOGICAL MARKER; CARBOPLATIN; CISPLATIN; PLATINUM COMPLEX; ANTINEOPLASTIC AGENT;

APOPTOSIS; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPARATIVE STUDY; DRUG MECHANISM; DRUG PREFERENCE; DRUG RESPONSE; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; FEMALE GENITAL TRACT CANCER; GERM CELL TUMOR; HEAD AND NECK CANCER; HUMAN; MALIGNANT MESOTHELIOMA; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NON SMALL CELL LUNG CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RADIOSENSITIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEMINOMA; SIDE EFFECT; SMALL CELL LUNG CANCER; SOLID TUMOR; STOMACH CARCINOMA; SURVIVAL RATE; TESTIS NONSEMINOMA CANCER; UTERINE CERVIX CANCER; FEMALE; NEOPLASMS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARBOPLATIN; CISPLATIN; FEMALE; HUMANS; NEOPLASMS;

EID: 84963800478     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2016.03.014     Document Type: Review

References (98)

1. Adelstein D., Li Y., Adams L., et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J. Clin. Oncol. 2003, 21:92-108.
2. Alderden R., Hall M., Hambley T. The discovery and development of cisplatin. J. Chem. Educ. 2006, 83:728-734.
3. Alsop K., Fereday S., Meldrum C., deFazio A., Emmanuel C., George J., et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J. Clin. Oncol. 2012, 30:2654-2663.
4. Andrews P.A., Mann S.C., Albright K.D., et al. Role of the Na+, K(+)-adenosine triphosphatase in the accumulation of cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells. Cancer Res. 1991, 51:3677-3681.
5. Armstrong D., Burdy B., Burger R., et al. Intraperitoneal Cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 2006, 354:34-43.
6. Azzoli C.G., Baker S., Tremin S., et al. American Society of Clinical Oncology Clinical Practise Guideline Update on chemotherapy for stage IV non-small cell lung cancer. J. Clin. Oncol. 2009, 27(36):6251-6266.
7. Bajorin D.F., Sarosdy M.F., Pfister D.G., Mazumdar M., Motzer R.J., Scher H.I., et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J. Clin. Oncol. 1993, 11:598-606.
8. Becker M., De Bastiani M., Klamt F., et al. High Cofilin-1 levels correlate with Cisplatin resistance in lung adenocarcinomas. Tumour Biol. 2014, 35(2). 1233-8.
9. Berek J.S., Bertelsen K., Willemse P.H., et al. Epithelial ovarian cancer (advanced stage): consensus conference (1998). Gynecol. Obstet. Fertil. 2000, 28:576-583.
10. Bernier J., Domenge C., Glebbeke M., et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 2004, 350:1945-1952.
11. Bernier J., Cooper J., Pajak T., et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of EORTC (#22931) and RTOG (#9501. Head Neck 2005, 27:843-850.
12. Birch R., Williams S., Cone A., Einhorn L., Roark P., Turner S., et al. Prognostic factors for favorable outcome in disseminated germ cell tumors. J. Clin. Oncol. 1986, 4:400-407.
13. Bokemeyer C., Kohrmann O., Tischler J., Weissbach L., Rath U., Haupt A., et al. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors. Ann. Oncol. 1996, 7:1015-1021.
14. Bokemeyer C., Kollmannsberger C., Stenning S., Hartmann J.T., Horwich A., Clemm C., et al. Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials. Br. J. Cancer 2004, 91:683-687.
15. Booton R., Ward T., Ashcroft L., Morris J., Heighway J., Thatcher N. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J. Thorac. Oncol. 2007, 2:902-906.
16. Bosl G.J., Geller N.L., Bajorin D., Leitner S.P., Yagoda A., Golbey R.B., et al. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J. Clin. Oncol. 1988, 6:1231-1238.
17. Briasoulis E., Kalofonos H., Bafaloukos D., et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J. Clin. Oncol. 2000, 18:3101-3107.
18. Castagneto B., Botta M., Aitini E., et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann. Oncol. 2008, 9:370-373.
19. Ceresoli G.L., Zucali P., Faveretto A.G., et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J. Clin. Oncol. 2006, 24:1443-1448.
20. Cetina L., Garcia-Arias A., Uribe Mde J., Candelaria M., Rivera L., Onate-Ocana L., et al. Concurrent chemoradiation with carboplatin for elderly, diabetic and hypertensive patients with locally advanced cervical cancer. Eur. J. Gynaecol. Oncol. 2008, 29:608-612.
21. Chan B.A., Coward J.I. Chemotherapy advances in small-cell lung cancer. J. Thorac. Dis. 2013, 5. S565-78.
22. Chitapanorux I., Lorvidhaya V., Ford J., et al. Chemoradiation comparing Cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: Randomised, non-inferiority, open trial. Eur. J. Cancer 2007, 43:1399-1406.
23. Cobo M., Isla D., Massuti B., Montes A., Sanchez J.M., Provencio M., et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J. Clin. Oncol. 2007, 25:2747-2754.
24. Collaboration ABCAM-a Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur. Urol. 2005, 48:202-206.
25. Cooper J.S., Guo M., Leichman L.L., et al. Chemoradiotherapy of locally advanced oesophageal cancer: long term follow-up of a prospective randomised trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999, 281:1623-1627.
26. Culine S., Lotholary A., Voigt J., et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomised phase II study-trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J. Clin. Oncol. 2003, 21:3479-3482.
27. Cunningham D., Allum W.H., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for resectable gastroeosophageal cancer. N. Engl. J. Med. 2006, 355:11-20.
28. Dann R.B., DeLoia J.A., Timms K.M., Zorn K.K., Potter J., Flake D.D., et al. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer. Gynecol. Oncol. 2012, 125:677-682.
29. De Castria T.B., DeSilva E.M., Gois A.F., Riera R. Cisplatin versus Carboplatin in combination with third generation drugs for advanced non-small cell lung cancer. Cochrane Database Syst. Rev. 2013, 8:CD009256.
30. De Santis M., Bellmunt J., Sylvester R., et al. Randomised phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II results of EORTC study 30986. J. Clin. Oncol. 2009, 27:5634-5639.
31. DiSaia, P.J., Creasman, W.T. (Eds.), 2012. Clinical Gynaecologic Oncology, 8th ed., Saunders Elsevier Inc., 51-120 (Chapter 3).
32. Dimopoulos M.A., Papadopoulou M., Andreopoulou E., Papadimitriou C., Pavlidis N., Aravantinos G., et al. Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: a Hellenic Cooperative Oncology Group study. Gynecol. Oncol. 1998, 70:70-74.
33. Dogliotti L., Carteni G., Marini L., et al. Gemcitabine plus Cisplatin versus gemcitabine plus carboplatin as first line chemotherapy in advanced transitional cell carcinoma of the urothelium: result of a randomised phase II trial. Eur. Urol. 2007, 52:134-141.
34. Du Bois A., Luck H., Pfisterer J., et al. A randomised clinical trial of Cisplatin/paclitaxel versus carboplatin/paclitaxel as first line treatment of ovarian cancer. J. Natl. Cancer Inst. 2003, 95:1320-1329.
35. Duenas-Gonzalez A., Cetina L., Sanchez B., Gomez E., Rivera L., Hinojosa J., et al. A phase I study of carboplatin concurrent with radiation in FIGO stage IIIB cervix uteri carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2003, 56:1361-1365.
36. El Rayes B.F., Shields A., Zalupski M., et al. A phase II study of carboplatin and paclitaxel in esophageal cancer. Ann. Oncol. 2004, 15:960-965.
37. El-Rayes B., Shields A., Philip P., et al. A phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary. Am. J. Clin. Oncol. 2005, 28:152-156.
38. Forastiere A., Metch B., Williamson S., et al. Randomised comparison of Cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of head and neck: a Southwest Oncology Group Study. J. Clin. Oncol. 1992, 10:1245-1251.
39. Greco F.A., Erland J., Hainsworth J., et al. Carcinoma of unknown primary site: phase II trials with docetaxel plus Cisplatin or Carboplatin. Ann. Oncol. 2000, 11:211-215.
40. Green J.A., Kirwan J.M., Tierney J.F., Symonds P., Fresco L., Collingwood M., et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 2001, 358:781-786.
41. Greimel E., Bjelic-Radisic V., du Bois A., et al. Randomised study of the Arbeitsgemeinschaft Gynaekologishe Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with Cisplatin/paclitaxel versus carboplatin/paclitaxel. J. Clin. Oncol. 2006, 24:579-586.
42. Gross-Goupil M., Fourcade A., Blot E., et al. Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial. Eur. J. Cancer 2012, 48:721-727.
43. Hale J., Olson T., Nicholson J., Dang M., Krailo M., Billmire D., et al. Carboplatin (CBP) versus cisplatin (CP) within prognostic groups in pediatric extracranial malignant germ cell tumors (MGCTs). J. Clin. Oncol. 2012, 30.
44. Hall M.D., Okabe M., Gottesman M., et al. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu. Rev. Pharmacol. Toxicol. 2008, 48:495-535.
45. Hermann G., Heffeter P., Koellenspenger G., et al. In vitro studies on Cisplatin focusing on kinetic aspects of intracellular chemistry by LC-ICP-MS. Metallomics 2013, 5(6). 636-47.
46. Horwich A., Sleijfer D.T., Fossa S.D., Kaye S.B., Oliver R.T., Cullen M.H., et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J. Clin. Oncol. 1997, 15:1844-1852.
47. Huebner G., Link H., Kohne C.H., et al. Paclitaxel and carboplatin versus gemcitabine and vinorelbine in patients with adenocarcinoma or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. Br. J. Cancer 2009, 100:44-49.
48. Humber C., Tierney J., Symonds R., et al. Chemotherapy for advanced, recurrent and metastatic endometrial cancer: a systemic review of Cochrane collaboration. Ann. Oncol. 2007, 18:409-420.
49. Husain A., He G., Venkatraman E.S., Spriggs D.R. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res. 1998, 58:1120-1123.
50. Ikuta K., Takemura K., Nishimura M., et al. Expression of multidrug resistance proteins and accumulation of cisplatin in human nonsmall cell lung cancer cells. Biol. Pharm. Bull. 2005, 28:707-712.
51. Ishida S., Lee J., Herskowitz I., et al. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc. Natl. Acad. Sci. 2002, 99:14298-14302.
52. Jeremic B., Zivic D., Marinkovic J., et al. Cisplatin and 5-fluorouracil as induction chemotherapy followed by radiation therapy in metastatic squamous cell carcinoma of an unknown primary localised to the neck: phase II study. J. Chemother. 1993, 5:262-265.
53. Karam I., Jiang S., Schellenberg D., et al. Outcomes of small cell lung cancer patients treated with Cisplatin-etoposide versus carboplatin-etoposide. Am. J. Clin. Oncol. 2015, 38(1). 51-4.
54. Katirtozoglou N., Gkiozos I., Markrilla N., et al. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study. Clin. Lung Cancer 2010, 11:30-35.
55. Kharsur T., Allred C., Anand V., et al. Cisplatin and 5-fluorouracil for metastatic squamous cell carcinoma from unknown primary. Cancer Invest. 1995, 13:263-266.
56. Kitagawa R., Katsumata N., Ando M., et al. A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer. Gynecol. Oncol. 2012, 125:307-311.
57. Lord R.V., Brabender J., Gandara D., Alberola V., Camps C., Domine M., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res. 2002, 8:2286-2291.
58. Mariette C., Dahan L., Mornex F., et al. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J. Clin. Oncol. 2014, 32:2416-2422.
59. McNeil E.M.D. DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy. Nucleic Acids Res. 2012, 40:9990-10004.
60. Mead G.M., Stenning S.P. The International Germ Cell Consensus Classification: a new prognostic factor-based staging classification for metastatic germ cell tumours. Clin. Oncol. (R. Coll. Radiol.) 1997, 9:207-209.
61. Metzger R., Leichman C.G., Danenberg K.D., Danenberg P.V., Lenz H.J., Hayashi K., et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J. Clin. Oncol. 1998, 16:309-316.
62. Milczek T., Klasa-Mazukiewicz D., Emerich J., et al. Regimens with intraperitoneal Cisplatin plus intravenous cyclophosphamide and intraperitoneal carboplatin plus intravenous cyclophosphamide are equally as effective in second line intraperitoneal chemotherapy for advanced ovarian cancer. Adv. Med. Sci. 2012, 57:46-50.
63. Miller D., Filiaci V., Fleming G., Mannel R., Cohn D. Matsumoto tea. Randomized phase III noninferiority trial of first-line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 2012, 125:771-773.
64. Muallem M.Z., Marnitz S., Richter R., Kohler C., Sehouli J., Arsenic R. ERCC1 expression as a predictive marker of cervical cancer treated with cisplatin-based chemoradiation. Anticancer Res. 2014, 34:401-406.
65. Mukhopadhyay A., Plummer E.R., Elattar A., Soohoo S., Uzir B., Quinn J.E., et al. Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival. Cancer Res. 2012, 72:5675-5682.
66. Nomura H., Aoki D., Yaegashi N., et al. Randomised phase II study comparing docetaxel plus Cisplatin, docetaxel plus carboplatin and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial cancer: a Japanese Gynaecologic Oncology Study Group (JGOG2041). Ann Oncol 2011, 22:636-642.
67. NSCLC Meta-Analyses Collaborative Group Chemotherapy in addition to supportive care improve overall survival in advanced non-small cell lung cancer: A systemic review and meta-analysis of individual patient data from 16 randomized control trials. J. Clin. Oncol. 2008, 26. 4617-4615.
68. Ozols R., Bundy B., Baergen R., et al. Phase III trial of carboplatin and paclitaxel compared with Cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynaecologic Oncology Group Study. J. Clin. Oncol. 2003, 21:3194-3200.
69. Palmieri C., Gojis O., Faratian D., et al. Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance. Br. J. Cancer 2013, 108:2039-2044.
70. Park J.H., Lee S.W., Park K.H., et al. Combination of gemcitabine and carboplatin as first-line treatment in elderly patients or those unfit for Cisplatin-based chemotherapy with advanced transitional cell carcinoma of the urinary tract. Cancer Chemother. Pharmacol. 2013, 71:1033-1039.
71. Peters W., Liu P., Barrett R., et al. Concurrent chemotherapy and pelvic radiation compared with pelvic radiation alone as adjuvant therapy after radical surgery in high-risk early stage cancer of the cervix. J. Clin. Oncol. 2000, 18:1606-1613.
72. Pignon J.P., Tribodet H., Scagliotti G.V., et al. Lung adjuvant Cisplatin evaluation: a pool analysis by LACE Collaborative Group. J. Clin. Oncol. 2008, 26:3552-3559.
73. Pittman K., Olver I., Price T., et al. Gemcitabine and carboplatin in carcinoma of unknown primary site: phase II Adelaide cancer trial and education collaborative study. Br. J. Cancer 2006, 95:1309-1313.
74. Rades D., Ulbricht T., Schild D., et al. Cisplatin superior to carboplatin in adjuvant radiochemotherapy for locally advanced cancers of the pharynx and oral cavity. Strahlenther. Onkol. 2012, 188:42-48.
75. Reed E., Dabholkar M., Chabner B. Platinum Analogues Cancer Chemotherapy 1996, 357. Lippincott-Raven Publishers, Philadelphia.
76. Reed E. Platinum-DNA adduct, nucleotide excision repair, and platinum based anti-cancer chemotherapy. Cancer Treat. Rev. 1998, 24:331-344.
77. Rossi A., DiMaio M., Chiodini P., et al. Carboplatin- or Cisplatin-based chemotherapy in first line treatment of small cell lung cancer: the COCIS meta-analysis of individual patient data. J. Clin. Oncol. 2012, 30:1292-1698.
78. Safra T., Shamai S., Grisaru D., et al. Weekly Carboplatin with paclitaxel compared to standard three-weekly treatment in advanced epithelial ovarian carcinoma: a retrospective study. Gynecol. Oncol. 2013, 132:18-22.
79. Santoro A., O'Brien M., Manegold C., et al. Pemetrexed plus Cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the international expanded access program. J. Thorac. Oncol. 2008, 3:756-763.
80. Scagliotti G.V., Parikh P., von Pawel J., et al. Phase III study comparing Cisplatin plus Gemcitabine with Cisplatin plus Pemetrexed in chemotherapy-naïve patients with advance stage non-small cell lung cancer. J. Clin. Oncol. 2008, 26:3543-3551.
81. Schuette W., Groashel A., Sebastian M., et al. A randomised Phase II Study of Pemetrexed in combination with Cisplatin or Carboplatin as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer. Clin. Lung Cancer 2013, 3:215-223.
82. Selvakumaran M., Pisarcik D.A., Bao R., Yeung A.T., Hamilton T.C. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res. 2003, 63:1311-1316.
83. Shen J., Wei J., Wang H., et al. SULF2 methylation is associated with in vitro cisplatin sensitivity and clinical efficacy for gastric cancer patients treated with a modified FOLFOX regimen. PLoS One 2013, 8(10):e75564.
84. Shirota Y., Stoehlmacher J., Brabender J., Xiong Y.P., Uetake H., Danenberg K.D., et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol. 2001, 19:4298-4304.
85. Song W.A., Zhou N.K., Wang W., et al. Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomised control trials. J. Thorac. Oncol. 2010, 5:510-516.
86. Sprowl J., Ness R., Sparreboom A. Polymorphic transporters and platinum pharmacodynamics. Drug Metab. Pharmacokinet. 2013, 28:19-27.
87. Stadlmann S., Dirnhofer S., Guth U., et al. ERCC1-immunoexpression does not predict platinum-resistance in ovarian cancer. Gynecol. Oncol. 2008, 108:252-253.
88. Sternberg C.N., de Mulder P.H., Schornagel J.H., et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J. Clin. Oncol. 2001, 19. 2638-46.
89. Strauss G.M., Hemdon J., Maddaus M.A., et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small cell lung cancer: CALGB 9633 with the Cancer and Leukaemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J. Clin. Oncol. 2008, 26:5043-5051.
90. Tewari D., Java J.J., Salani R., Armstrong D.K., Markman M., Herzog T., et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 2015, 33:1460-1466.
91. VanCustem E., Moisteyenko V.M., Tjulandin S.A., et al. Phase III study of docetaxel and Cisplatin plus fluorouracil compared with Cisplatin and fluorouracil as first-line treatment for advanced gastric cancer: a report of the V325 Study Group. J. Clin. Oncol. 2006, 24:4991-4997.
92. Van Der Maase H., Sengelov L., Robert J.T., et al. Long term survival results of a randomized trial comparing gemcitabine plus Cisplatin with methotrexate, vinblastine, doxorubicin and Cisplatin in patients with bladder cancer. J. Clin. Oncol. 2005, 23:4602-4608.
93. Van Hagen P., Hulshof M.C., vander Graast A., et al. Preoperative chemoradiotherapy for oesophageal or junctional cancer. N. Engl. J. Med. 2012, 366:2074-2084.
94. Van der Maase H., Hansen S.W., Robert J.T., et al. Gemcitabine and Cisplatin versus methotrexate, vinblastine, doxorubicin and Cisplatin in advanced or metastatic bladder cancer: result of a large, randomised, multinational, multicentre, phase III study. J. Clin. Oncol. 2000, 18:3068-3077.
95. Vermorken J., Mesia R., Hitt R., et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 2008, 359:1116-1127.
96. Vogelzang N.J., Rusthoven J.J., Symanoski J., et al. Phase III study of pemetrexed in combination with Cisplatin versus Cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2003, 21:2636-2644.
97. Williams S., Blessing J.A., Liao S.Y., et al. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. J. Clin. Oncol. 1994, 12:701-706.
98. Ychou M.B.V., Pignon J.-P., et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicentre phase III trial. J. Clin. Oncol. 2011, 29:1715-1721.